The European Society of Cardiology (ESC) Congress 2024 event held in London during 30th August – 2nd September 2024, displayed groundbreaking research, practice-changing science and opportunities shaping the future of cardiovascular medicine. The event focused on personalizing cardiovascular care, with an emphasis on enhancing patient outcomes.
Hypertension Management: New ESC 2024 Guidelines for Hypertension and Renal Denervation:
- The new ESC guidelines outline patient selection criteria inclusive of adult patients with uncontrolled and resistant hypertension. The focus was on patients with high cardiovascular risk who remain uncontrolled and prefer to undergo renal denervation (RDN) through a customized, shared decision-making approach.
- Clinical evidence gathered from Medtronic Symplicity blood pressure procedure was the major contributor for laying down the ESC guidelines. The Medtronic RDN clinical program was backed by experience in over 25,000 patients treated globally with over 4,000 patients in the presence and absence of medication, and in patients with high baseline cardiovascular risk, or with comorbidities.
Global Pivotal Trial Results for EV-ICD Reveal High Success Rates in Antitachycardia Pacing (ATP) and Effective Defibrillation:
- Medtronic presented long-term results from the global Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Pivotal Trial, highlighting the continued performance and safety of the EV-ICD system for patients at risk of sudden cardiac death. Analysis of the presented results demonstrated that anti-tachycardia pacing (ATP) was successful and in line with transvenous ATP success.
- The study demonstrated that ATP is an effective and safe method to terminate ventricular tachycardia (VT)/ventricular fibrillation (VF), and that EV-ICD is effective in treating patients with life-threatening arrhythmias and could offer a reliable option for managing these conditions. The success of ATP and defibrillation could mean improved patient outcomes, reduced need for additional interventions, and potentially fewer side effects related to defibrillation shocks.
AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments:
- GE HealthCare displayed its latest technology of high-quality imaging to the patient’s bedside, cardiac catheterization laboratory and other hospital settings. The ultraportable Oscan Air SL with Caption AI helps capture cardiac images for better informing diagnoses and patient treatment plans. Access to this novel technology enables earlier heart disease detection and expands cardiac care into primary care and emergency settings. After capturing an image, the Ateef feature uses AI to automatically calculate the left ventricular ejection fraction (LVEF), a crucial indicator of heart function.
- Philips introduced the next advancement in echocardiography, utilizing its AI-driven capabilities to accelerate and automate the diagnosis of echocardiographic measurements. Philips’ platform featured innovative artificial intelligence (AI) tools designed to support the diagnosis of structural heart disease (SHD), including a new automated 3D tricuspid valve quantification tool, and new 3D collar flow quantification to assist in diagnosing mitral regurgitation.
Philips’ latest AI applications, such as the Auto Segmental Wall Motion Scoring and AutoStrain tools, demonstrated quick capabilities to detect subtle early warning signs of cardiotoxicity during treatment. Detection of these early warning signs aids cancer treatment and prevents symptomatic or irreversible cardiotoxicity.
- Siemens Healthineers displayed the Acuson Origin, a specialized cardiovascular ultrasound system featuring advanced AI capabilities. This system is designed to enhance the entire spectrum of cardiovascular care, including diagnostic, structural heart, electrophysiological, and paediatric procedures. Its standout innovation is a suite of AI-powered features for measurements, view recognition, and imaging assistance. With over 500 AI-driven measurements for transthoracic and transoesophageal echocardiography, the Acuson Origin aims to improve cardiovascular workflows and minimize variability. The system also delivers automated contouring and quantification of all four cardiac chambers without the need for an electrocardiogram (ECG) via the 2D and 4D HeartAI features.
Next Generation Cardiovascular Ultrasound Enhanced with Cardiology Informatics:
Philips’ latest AI-enabled cardiovascular ultrasound platform featured the industry-first applications designed to accelerate cardiac ultrasound analysis with proven technology. Integrated with Philips Ultrasound Workspace, the platform supports diagnostic capabilities on and off-cart, allowing for advanced analysis of vendor-agnostic data to enhance confident decision-making.
Detecting Possible AFib at an Early Stage:
At the ESG Congress, OMRON showcased its new “OMRON M7 Intelli IT AFib,” an advanced blood pressure monitor capable of detecting possible atrial fibrillation (AFib) during every blood pressure measurement. Screening for AFib during home blood pressure monitoring provides a convenient and effective method for early detection of AFib, helping to enhance heart health and ensure widespread access to preventive care.
First All-Female TAVI Trial Shows Excellent Outcomes:
- Edwards Lifesciences presented results from the RHEIA Trial; a pioneering study dedicated solely to evaluating outcomes for women undergoing transcatheter aortic valve implantation (TAVI). Investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 or SAPIEN 3 Ultra valves as compared to those receiving surgical aortic valve replacement (SAVR).
- The success of the TAVI group underscores the critical importance of valve selection for women undergoing aortic valve replacement, particularly those with small annuli. This careful selection helps preserve future options for valve-in-valve procedures, ensuring ongoing management of their condition.
Smart Ring in Night-Time Blood Pressure Monitoring:
South Korean health-tech startup Sky Labs demonstrated a smart ring – CART BP – that it has developed to make it easier for physicians to treat hypertension in patients. The smart ring uses sensors to measure photoplethysmography (PPG) — volumetric changes in a wearer’s blood circulation — while offering continuous blood-pressure monitoring day and night. Sky Labs’ sessions revealed demonstrated the unique features and functionalities of CART BP in night-time blood pressure monitoring. The startup also presented clinical data and research findings on the effectiveness of cuffless monitoring and its implications on continuous blood pressure monitoring.
About Frost & Sullivan:
Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem. Our transformation journey is fueled by four powerful components, ensuring your success in navigating the ever-changing landscape of your industry.
- Schedule a complimentary Growth Dialog with our team to dive deeper into transformational strategies and explore specific needs within your company.
- Become a Frost Growth Expert in your area of specialization and share your expertise and passion with the community through our think tanks.
- Join Frost & Sullivan’s Growth Council and become an integral member of a dynamic community focused on identifying growth opportunities and addressing critical challenges that influence your industry.
- Designate your company as a Companies to Action to increase exposure to investors, new M&A opportunities, and other growth prospects for your business.
To explore growth opportunities in cardiovascular medicine, connect with our growth experts at:
Dr. Bejoy Daniel – Growth Expert & Senior Industry Analyst – bejoy.daniel@frost.com
Vittal Bhaskar Rao – Growth Expert & Research Manager – vittal.rao@frost.com
Anantharaman Viswanathan – Growth Expert & Research Director – anantharaman.viswanathan@frost.com
